tozorakimab

Home
Ligands
tozorakimab

GtoPdb Ligand ID: 12964

Synonyms: MEDI-3506 | MEDI3506

Comment: Tozorakimab (MEDI3506) is a high-affinity anti-IL-33 monoclonal antibody. It inhibits IL-33-induced signalling to produce an anti-inflammatory effect [2]. Tozorakimab blocks the actions of both reduced IL-33 (IL-33^red) and oxidized IL-33 (IL-33^ox) metabolites through their respective downstream pathways (ST2 for IL-33^red, RAGE/EGFR complex for IL-33^ox) [1,3-4].

References
1. Cohen ES, Scott IC, Majithiya JB, Rapley L, Kemp BP, England E, Rees DG, Overed-Sayer CL, Woods J, Bond NJ et al.. (2015) Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat Commun, 6: 8327. [PMID:26365875]
2. England E, Rees DG, Scott IC, Carmen S, Chan DTY, Chaillan Huntington CE, Houslay KF, Erngren T, Penney M, Majithiya JB et al.. (2023) Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. Sci Rep, 13 (1): 9825. [PMID:37330528]
3. Strickson S, Houslay KF, Negri VA, Ohne Y, Ottosson T, Dodd RB, Chaillan Huntington C, Li J, Killick H, Rees DG et al.. (2022) Oxidised IL-33 signals via RAGE/EGFR to drive a COPD-associated phenotype. European Respiratory Journal, 60: 2482. DOI: 10.1183/13993003.congress-2022.2482
4. Tominaga S. (1989) A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett, 258 (2): 301-4. [PMID:2532153]
5. Wilkinson T, Dixon R, Page C, Carroll M, Griffiths G, Ho LP, De Soyza A, Felton T, Lewis KE, Phekoo K et al.. (2020) ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. Trials, 21 (1): 691. [PMID:32736596]

References

1. Cohen ES, Scott IC, Majithiya JB, Rapley L, Kemp BP, England E, Rees DG, Overed-Sayer CL, Woods J, Bond NJ et al.. (2015)
Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation.
Nat Commun, 6: 8327. [PMID:26365875]

2. England E, Rees DG, Scott IC, Carmen S, Chan DTY, Chaillan Huntington CE, Houslay KF, Erngren T, Penney M, Majithiya JB et al.. (2023)
Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction.
Sci Rep, 13 (1): 9825. [PMID:37330528]

3. Strickson S, Houslay KF, Negri VA, Ohne Y, Ottosson T, Dodd RB, Chaillan Huntington C, Li J, Killick H, Rees DG et al.. (2022)
Oxidised IL-33 signals via RAGE/EGFR to drive a COPD-associated phenotype.
European Respiratory Journal, 60: 2482. DOI: 10.1183/13993003.congress-2022.2482

4. Tominaga S. (1989)
A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor.
FEBS Lett, 258 (2): 301-4. [PMID:2532153]

5. Wilkinson T, Dixon R, Page C, Carroll M, Griffiths G, Ho LP, De Soyza A, Felton T, Lewis KE, Phekoo K et al.. (2020)
ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial.
Trials, 21 (1): 691. [PMID:32736596]